Reading QSI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track QSI free→Reading QSI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track QSI free→NASDAQHealth CareMedical DevicesSnapshot 2026-06-15
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is neutral, and management's recent track record has been steady. The company was unprofitable over the past year, so its earnings quality can't be assessed. Risk is high, and the sector backdrop is a headwind, with QSI trading below typical compared to sector peers. Peer multiples imply a price about 369% below where it trades (it looks expensive on this basis); the read is rich, as it trades above peer multiples, and the longer horizon does not make that back through growth. This assessment is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 1 valuation methods, at three horizons. Current price $0.99. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $0.99, QSI's earnings are too small for P/E to mean much; on sales it trades at 66× p/s (22.3× the 3× p/s peer median). That gap is an optionality premium a financial-multiple model can't price — our $0.28 fair value covers only the as-is business, low confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 257% of near-term growth above a flat-multiple fair value; not enough history to forecast a comparison. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Flags: expensive valuation, a turbulent sector regime (Heating).
For similar setups historically (n=2,301): about 43% saw a 20%+ drawdown, and roughly 77% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 0.91x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
4 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.00 → $-0.10. 1 raised, 0 cut, 1 covering analysts.
0 upgrades, 0 downgrades / 30d. 67% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$351.
How much price usually moves either way.
On a bad day, this stock has moved -$802.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $7,295.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: A drop in revenue would show ongoing struggles in a maturing sector. Investors will react to signs of weakness.
Confirms:Q2 earnings report shows revenue declining year over year by more than 10%.
Disproves:Q2 earnings report shows revenue growth year over year or stabilizes.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for QSI yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On May 7, 2026 , Quantum-Si Incorporated (the “Company”) issued a press release announcing its results for the three months ended March 31, 2026 and provided a business update. A copy of the press release is furnished as Exhibit 99.1 hereto. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Equipment.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
QSI Quantum-Si, Inc. | Below typical Show detailsSector percentile: 21 of 100 | expensive | high |
ABT Abbott Laboratories | Above typical Show detailsSector percentile: 94 of 100 | fair | moderate |
ISRG Intuitive Surgical | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
SYK Stryker Corporation | Above typical Show detailsSector percentile: 71 of 100 | fair | moderate |
MDT Medtronic | Above typical Show detailsSector percentile: 89 of 100 | fair | moderate |
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
The company aims to achieve approximately $1 million in revenue for the full year 2026.
Stated in 2 of last 2 quarters. Revenue was $258,000 in 2026-Q1, indicating progress towards the $1 million target for 2026. The company has reiterated this revenue goal, but current revenue suggests limited progress towards the annual target.
“The company reiterated its revenue guidance for 2026: approximately $1.0 million.”
“The company provided the following financial guidance: Revenue: Approximately $1.0 million.”
The company aims to keep adjusted total operating expenses at $98 million or less for 2026.
Newly stated in 2026-Q1. Operating income was -$24.05M in 2026-Q1, indicating a need for cost control to meet the $98M annual expense target. The company has set this as a priority, but current expenses suggest significant effort is required to achieve it.
“Adjusted total operating expenses: $98.0 million or less for 2026.”
The company plans to limit total cash usage to $93 million or less for the full year 2026.
Newly stated in 2025-Q4. Cash from operating activities was -$25.64M in 2026-Q1, indicating a challenging path to limit cash usage to $93M for the year. The company has set this as a priority, but current cash flow suggests significant constraints.
“Total cash usage: $93.0 million or less for 2026.”
Why it matters: If health care revenue growth speeds up, it could lift Quantum-Si's prospects. This would indicate a healthier market.
Confirms:Health care sector revenue growth is speeding up again. It is getting close to 10% each year.
Disproves:Health care sector revenue growth continues to decelerate below 5% year over year.
Results of Operations and Financial Condition. On March 3, 2026, Quantum-Si Incorporated (the “Company”) issued a press release announcing its results for the fourth quarter and full year ended December 31, 2025 and provided a business update. A copy of the press release is furnished as Exhibit 99.1 hereto. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended…
Results of Operations and Financial Condition. On November 5, 2025 , Quantum-Si Incorporated (the “Company”) issued a press release announcing its results for the three and nine months ended September 30, 2025 and provided a business update. A copy of the press release is furnished as Exhibit 99.1 hereto. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (t…
Entry into a Material Definitive Agreement. On September 23, 2025, Quantum-Si Incorporated (the “Company”) and Winchester Office LLC (“Winchester”) entered into a Settlement and Mutual Release Agreement (the “Mutual Release Agreement”) in connection with a lease dated December 28, 2021, by and between the Company, as tenant, and Winchester, as landlord (the “Lease Agreement”), for certain premises in the building located at 115 Munson Street, New Haven, CT, 06511 (the “Premises”). The Lease A…
Termination of a Material Definitive Agreement. The information contained in